Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Laurent Meijer, Deborah J. Nelson, Vladimir Riazanski, Aida G. Gabdoulkhakova, Geneviève Héry-Arnaud, Rozenn Le Berre, Nadège Loaëc, Nassima Oumata, Hervé Galons, Emmanuel Nowak, L. Guéganton, Guillaume Dorothée, Michaela Prochazkova, Bradford Hall, Ashok B. Kulkarni, Robert D. Gray, Adriano Giorgio Rossi, Véronique Witko‐Sarsat, Caroline Norez, Frédéric Becq, Denis Ravel, Dominique Mottier, G. Rault
Journal of Innate Immunity · 2016 · 5,008 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Guéganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A. B., Gray, R. D., Rossi, A. G., Witko‐Sarsat, V., Norez, C., … Rault, G. (2016). Modulating innate and adaptive immunity by (R)-Roscovitine: Potential therapeutic opportunity in cystic fibrosis. Journal of Innate Immunity, 8(4), 330–349. https://doi.org/10.1159/000444256
In text: (Meijer et al., 2016)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammatory lymphocytes and reduced production of various interleukins, notably IL-17A) contribute to the resolution of inflammation and restoration of innate immunity, and (4) roscovitine displays analgesic properties in animal pain models. The fact that (R)-roscovitine has undergone extensive preclinical safety/pharmacology studies, and phase I and II clinical trials in cancer patients, encourages its repurposing as a CF drug candidate.
Related papers
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report2014
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis2006
- IL-17 and Th17 Cells2009
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammation2005
- Follicular Helper CD4 T Cells (T FH )2011
Metadata from OpenAlex (CC0). Citations are generated from the published record.